Odgovor Če feb 08, 2018 07:43

Latest Alzheimer's Flop Raises Doubts About 'Amyloid Hypothe

Even after Eli Lilly announced that its experimental Alzheimer’s drug solanezumab had failed in clinical trials in late 2016, it continued investigating its potential in patients at the very earliest stages of the memory-stealing disease. The hope was that if the drug could eliminate soluble amyloid-beta—the protein blamed for the brain plaques that form in patients—Alzheimer’s progression might be stopped, or at least slowed significantly.

That hope has now been dashed. New data from a trial called Expedition3, published in the New England Journal of Medicine, does not validate findings from earlier trials that indicated the drug might produce a modest slowdown in cognitive decline. There were 2,129 patients in this trial, all of whom had mild dementia due to Alzheimer’s, and about half received the drug every four weeks for 18 months. When their cognitive abilities were measured using a 14-part test, there was no significant difference between their performance at week 80 and that of patients given a placebo.

https://www.forbes.com/sites/arlenewein ... 375576412b
Vabljeni na moje spletne strani: www.gaspergrom.com